PRLD
NASDAQ · Biotechnology
Prelude Therapeutics Inc
$5.07
+0.24 (+4.97%)
Open$4.88
Previous Close$4.83
Day High$5.07
Day Low$4.83
52W High$5.91
52W Low$0.81
Volume—
Avg Volume379.4K
Market Cap431.68M
P/E Ratio—
EPS$-0.59
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+85.8% upside
Current
$5.07
$5.07
Target
$9.42
$9.42
$6.99
$9.42 avg
$10.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.44M | 132.26M | 127.36M |
| Net Income | -110,082,040 | 2.80M | 2.65M |
| Profit Margin | -819.6% | 2.1% | 2.1% |
| EBITDA | -113,794,296 | 4.42M | 4.16M |
| Free Cash Flow | — | 2.17M | 2.21M |
| Rev Growth | — | +3.8% | -1.6% |
| Debt/Equity | — | 0.63 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |